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BACKGROUND: Excess body weight and weight gain have been reported to independently increase the risk of several cancers.
There are few published studies in nationally representative populations of women on specific, ‘obesity-related’ cancers in relation
to prior weight change and relevant confounders.
METHODS: Based on self-reported anthropometry, we prospectively assessed body mass index (BMI), weight change over 6 years
and subsequent obesity-related cancer risk in the Norwegian Women and Cancer study. We used Cox proportional hazard models
to calculate hazard ratios and restricted cubic splines to model potential non-linear dose–response relationships.
RESULTS: Excess body weight increased the risk of overall obesity-related cancer, postmenopausal breast, colorectal, colon,
endometrial and kidney cancer, with endometrial cancer showing a threefold elevated risk. High weight gain ( ≥ 10 kg) increased
the risk of overall obesity-related cancer, postmenopausal breast, endometrial and pancreatic cancer. The association between high
weight gain and pancreatic cancer was strong, with 91% increased risk.
CONCLUSIONS: Maintaining stable weight in middle adulthood, irrespective of BMI category at baseline, and avoiding excess body
weight are both important in the prevention of several obesity-related cancers in women. Our finding of increased risk of
pancreatic cancer in women with moderate and high weight gain is novel.
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BACKGROUND
The prevalence of overweight and obesity has been increasing
continuously worldwide over the past four decades.1 Although
body weight is a modifiable factor, the attempts to halt the
obesity epidemic has failed. The global burden of cancer has
increased alongside the obesity prevalence, with 13 cancer types
defined as obesity-related.2,3 The cancers with sufficient evidence
of a positive association with overweight or obesity (also referred
to as excess body weight) are cancer of the breast (postmeno-
pausal), colon–rectum, endometrium, ovary, pancreas, kidney,
gallbladder, gastric cardia, liver, oesophagus (adenocarcinoma),
meningioma, thyroid and multiple myeloma. Weight gain is also
associated with several obesity-related cancers independent of
body composition.4 However, nationally representative studies on
weight gain and the risk of less-commonly diagnosed obesity-
related cancers such as pancreatic and kidney cancer in women
are rare. In fact, in the latest report from The World Cancer
Research Fund’s Continuous Update Project, the expert panel
concludes that postmenopausal breast cancer is the only cancer
for which there is strong evidence of an association with weight
gain.5 Thus, there is an evident research gap on weight gain and
specific obesity-related cancers.
In accordance with global trends, there are indications of
increased obesity prevalence in Norway. The latest regional health
examination from Nord-Trøndelag (HUNT), carried out in
2006–2008, reported a prevalence of obesity of 23.1% in women.
This represented a 10%-point increase from the previous HUNT
report covering the period 1984–1986.6 In addition, Statistics
Norway conduct a survey on living conditions every 3 years in a
representative sample of inhabitants in Norway aged 16 years or
older.7 Since 1998, the self-reported prevalence of obesity has
increased in both women and men and reached 11% in women in
2015. Surely, there are differences in obesity prevalence according
to age, region, rural/urban settlements and reporting method
(self-report or examination), however, there is little doubt that
increasing body weight is a public health concern also in Norway.
Moreover, three of the five most commonly diagnosed cancers
among women in Norway are obesity-related (breast, colon and
endometrial cancer) and the overall cancer incidence rate has
increased.8
In this study, we aimed to quantify separate risk estimates for
body mass index (BMI) and short-term weight change in a
nationally representative female cohort, for a large number of
obesity-related cancers, including pancreatic and kidney cancer.
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MATERIALS AND METHODS
Study design, participants and subsamples
The Norwegian Women and Cancer (NOWAC) study is a nationally
representative, population-based cohort study that was initiated
in 1991, with the aim of investigating the aetiology of cancer
among women in Norway. Women aged 30–70 years were
randomly sampled from the Norwegian Central Population
Register, which includes all Norwegian inhabitants, and invited
to participate in the study during three separate waves of
recruitment: 1991–1992, 1996–1997 and 2003–2005. Those who
agreed to participate completed an enrolment questionnaire (Q1)
and were invited to complete a follow-up questionnaire (Q2) 5–8
years after Q1. The response rate in the NOWAC study varied
between 48 and 57% at enrolment, and was 81% at follow-up. The
unique personal identity number assigned to every resident of
Norway allowed for linkages to national registers for complete
follow-up.9 The external validity in NOWAC is considered high as
the performed validation study showed that the distribution of
exposures was independent of the response rate and the
observed cumulative incidence of cancer vs expected national
figures from the Cancer Registry of Norway showed no substantial
differences.10 Details on the design, materials and procedures of
the NOWAC study have been described elsewhere.11
In the present study, 145,658 women who returned Q1 between
1991 and 2005 were considered eligible for inclusion (Fig. 1). We
excluded women who had emigrated or died before Q1 was
registered in the study database (n= 30), women who were
diagnosed with cancer (other than non-melanoma skin cancer)
prior to Q1 (n= 5112), and women with missing weight in both
Q1 and Q2 (n= 1678). Women who reported implausible weight
values ( < 30 or > 200 kg), height values ( < 100 or > 230 cm) (n=
4) or age at menopause ( < 25 or > 60 years) (n= 88) in either
questionnaire were also excluded. Thus, our final analytical study
sample consisted of 138,746 women: 40% enroled in 1991–1992,
31% enroled in 1996–1997 and 29% enroled in 2003–2005. BMI
and weight change analyses were carried out in subsamples of the
final analytical study sample. In the BMI analysis, we excluded
women with < 2 years of follow-up after Q1 to reduce the possible
influence of reverse causality from the effects of pre-clinical cancer
on weight (n= 1 565), and women with missing weight or height
in Q1 (n= 1473). In the weight change analysis, we excluded
women who did not return Q2 (n= 51 637). Women who returned
Q2 were younger, had lower body weight and were less likely to
use hormone therapy (HT) compared with women who completed
only Q1. Furthermore, we excluded women who emigrated or
died before Q2 was registered in the study database (n= 8).
Women who had been diagnosed with cancer (other than non-
melanoma skin cancer) prior to Q2 (n= 2030), had < 2 years of
follow-up after Q2 (n= 1174), or had missing information on
weight in Q1 or Q2 were also excluded (n= 2967).
In site-specific analyses, we excluded premenopausal women
from the postmenopausal breast cancer analysis (BMI analysis,
n= 76,377; weight change analysis n= 34,222), women who
reported hysterectomy from the endometrial cancer analysis (BMI
analysis, n= 7394; weight change analysis, n= 5035) and women
who reported bilateral oophorectomy from the ovarian cancer
analysis (BMI analysis n= 2341, weight change analysis n= 1907).
Follow-up and identification of cancer cases
Follow-up began at Q1 for the BMI analysis and at Q2 for the
weight change analysis. Women were followed-up until cancer
diagnosis, death, emigration or the end of follow-up (31
December 2014), whichever occurred first. Incidence of cancer,
death and emigration were identified through linkage to the
Norwegian Cancer Registry, the Cause of Death Registry and the
Norwegian Central Population Register, respectively. The outcome
of interest was first primary invasive cancer, for which evidence of
a positive association with excess body weight is considered
sufficient,2 hereafter, referred to as ‘obesity-related cancer’. These
cancers were assessed as one combined outcome (overall obesity-
related cancer) and as site-specific outcomes, and were classified
according to the International Classification of Diseases, 10th
Excluded:
Less than 2 years of follow-up after Q1, n=1,565
Missing weight or height values in Q1, n=1,473
Filled in enrolment questionnaire (Q1)
from 1991 to 2005
n=145,658
Excluded:
Dead or emigrated before registered Q1, n=30
Prior cancer diagnosis other than non-melanoma skin cancer at Q1, n=5,112
Missing weight values in Q1 and follow-up questionnaire (Q2), n= 1,678
Implausible values:
Weight <30 or >200 kg or height <100 or >230 cm, n=4
Age at menopause <25 or >60 years, n=88
BMI analysis subcohort (Q1)
n=135,708




No response to Q2, n=51,637
Dead or emigrated before registered Q2 questionnaire, n=8
Prior cancer diagnosis other than non-melanoma skin cancer at Q2, n=2,030
Less than 2 years of follow-up after Q2, n=1,174
Missing weight values in Q1 or Q2, n=2,967
Analytical study sample
n=138,746
Fig. 1 Flowchart of study participants
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Revision. They included cancer of the breast (postmenopausal)
(C50), colon–rectum (C18–20), endometrium (C54), ovary (C56),
pancreas (C25), kidney (C64), gallbladder (C23–24), gastric cardia
(C16), liver (C22), oesophagus (adenocarcinoma) (C15), menin-
gioma (C70–72), thyroid (C73) and multiple myeloma (C90). In the
overall obesity-related cancer analysis, women were considered to
have postmenopausal breast cancer if they reported being
postmenopausal in Q1, or if they gave an age at menopause that
was earlier than their age at breast cancer diagnosis. Women with
unknown menopausal status or missing information on age at
menopause were considered to have postmenopausal breast
cancer if they had reached 53 years of age at or before the time of
breast cancer diagnosis. This age cutoff has been used previously
to classify women as postmenopausal in the NOWAC study12 and
represents ~ 80% of the women in our study population who
reached natural menopause. We did not perform site-specific
analyses for cancer of the gallbladder, gastric cardia, liver,
oesophagus, meningioma, thyroid or multiple myeloma, owing
to the small number of incident cases for each of these sites.
Assessment of BMI, weight change and covariates
BMI was calculated as self-reported weight in kg divided by
the square of self-reported height in metres and categorised
according to the World Health Organisation definition:13 under-
weight (BMI < 18.5 kg/m2), normal weight (BMI 18.5 ≤ 25 kg/m2),
overweight (BMI 25 ≤ 30 kg/m2), or obesity (BMI ≥ 30 kg/m2). We
used self-reported weight from Q1 and Q2 to calculate weight
change, which was categorised into five groups: weight loss ( ≤ 2
kg), stable weight (−2– < 2 kg), low weight gain (2– < 5 kg),
moderate weight gain (5– < 10 kg) or high weight gain ( ≥ 10 kg).
Information on covariates was extracted from Q1 for the BMI
analysis, and Q1 or Q2 for the weight change analysis. An a priori
selection of covariates was done, based on findings from previous
studies on BMI or weight change and obesity-related cancer, as
well as previous reports from the NOWAC study. Thus, the
covariates education ( < 10 years/10–12 years/ > 12 years), physical
activity level (low/moderate/high), smoking status (never/former/
current) and alcohol intake ( ≤median/ >median g/day) were
included in all analyses. In addition, we assessed smoking
transition (cessation/restart/no change) and physical activity
change (increase/decrease/no change) in all weight change
analyses. The outcome-specific covariates that were common for
postmenopausal breast, ovarian and endometrial cancer were age
at menarche ( ≤median/ > median age), parity/age at first full-
term pregnancy (nullipara/unipara < 29 years/unipara ≥ 30/multi-
para < 29/multipara ≥ 30), oral contraceptive (OC) use (never/ever)
and HT use (never/former/current). For postmenopausal breast
cancer, maternal history of breast cancer (yes/no) was also
included in the model, and for endometrial and ovarian cancer,
menopausal status was also included in the model. Diabetes (yes/
no) was evaluated as a potential confounder for endometrial,
colorectal, pancreatic and kidney cancer; for colorectal cancer (as
well as for colon and rectal cancer analysed separately) we
assessed consumption of red and processed meat, fruits,
vegetables, fibre and calcium categorised into tertiles (low/
medium/high).
Statistical analysis
Population characteristics by BMI status and weight change
category were assessed using χ2 tests for categorical variables and
one-way analysis of variance or Kruskal–Wallis test for continuous
variables. We used Cox proportional hazard regression models
with age as the underlying time metric14 to estimate hazard ratios
and 95% confidence intervals (CI) for the associations of BMI and
weight change with obesity-related cancer risk. The reference
groups were ‘normal weight’ and ‘stable weight’. To account for
the calendar and birth cohort effect, we constructed a variable
based on wave of enrolment and birth year (categorised into four
groups) that was included in the Cox regression models, and
allowed the baseline hazard function to vary between the groups
but with equal coefficients across groups. The Cox models were
built according to the ‘purposeful selection’ approach.15 In brief,
we performed univariable Cox models for each covariate and
included those that were significant at a 20% level in a
multivariable model (the full model). Thereafter, we used Wald
statistics to exclude covariates that were no longer significant in
the full model, or did not change the coefficients of the exposure
variable > 20%. Log-likelihood ratio tests were performed to
compare goodness of fit between the reduced model and the full
model. Covariates that remained in the reduced final models are
presented in the footnotes of Tables 2 and 3. Participants with
missing information on included covariates were excluded from
the analyses. Tests based on Schoenfeld residuals showed no
evidence of violation of the proportional hazard assumptions.16
We fitted two models per outcome; Model 1 controlled only for
age (by time in the Cox regression) and Model 2 (main model)
with adjustments by purposeful selection of covariates for each
outcome separately. We tested for plausible interactions with log-
likelihood ratio test, comparing reduced models with and without
the interaction term. In all weight change analyses, we tested for
interaction between BMI status and weight change category. In
site-specific analyses where HT use or menopausal status was
included as a covariate, we tested for interactions between these
and each exposure. In order to model potential non-linear
dose–response relationships, we fitted restricted cubic spline
transformations (four knots) of the exposure variables.17 We
evaluated non-linearity by testing the null hypothesis of equal
spline coefficients. The knots were placed at equally spaced
percentiles as recommended by Harrell (2001).18 All statistical
analyses were performed using STATA version 15.1 (Stata Corp.,
College Station, TX, USA).
RESULTS
In total, 135,708 women were included in the BMI analysis and
80,930 women who also responded to Q2 were included in the
weight change analysis (Fig. 1). In the BMI analysis, average
follow-up time was 16.9 (standard deviation (SD)= 5.8) years,
during which 9328 obesity-related cancers were diagnosed, with
a mean age at diagnosis of 61.9 (SD= 7.9) years. In the weight
change analysis, average follow-up time was 13.1 (SD= 4.2)
years, during which 4831 obesity-related cancers were diag-
nosed, with a mean age at diagnosis of 63.0 (SD= 7.7) years. The
average response time between Q1 and Q2 was 6.3 years (SD=
0.9) and did not differ substantially across weight change
categories.
Population characteristics
In the BMI analysis, the population mean (SD) age, weight and BMI
were 48.2 (8.6) years, 66.7 (11.4) kg and 24.1 (3.9) kg/m2,
respectively. The majority of women were of normal weight
(64.6%), followed by overweight (25.5%), obesity (7.7%) and
underweight (2.2%) (Table 1). Compared with the other BMI
categories, women with obesity were older, and had lower
education, physical activity level and alcohol intake. They were
more likely to be never or former smokers, report lower age at
menarche, younger at first full-term pregnancy, have three or
more children, less likely to use OC and more likely to report
former use of HT.
In the weight change analysis, the population mean (SD) age,
weight and BMI in Q2 was 52.4 (8.5) years, 68.6 (11.5) kg and 24.8
(3.9) kg/m2, respectively. During the 6.3 years between Q1 and Q2,
9.7% of women lost weight, 29.3% had stable weight, 27.6% had
low weight gain, 24.1% had moderate weight gain and 9.3% had
high weight gain (Supplementary Information, Table S1). Popula-
tion characteristics differed across these weight change
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categories. Women with high weight gain were younger and
reported lower physical activity at Q1 compared with women with
stable weight. Moreover, between Q1 and Q2, women with high
weight gain were more likely to have stopped smoking, decreased
their physical activity level and transitioned to menopause.
BMI and obesity-related cancer risk
Compared with normal-weight women, women with overweight
or obesity had an increased obesity-related cancer risk, with HRs
of 1.09 (95% CI: 1.03–1.14) and 1.24 (95% CI: 1.14–1.34) (Table 2). In
site-specific analyses, endometrial cancer displayed a significant
association with obesity, with an almost threefold increased risk
(HR= 2.78, 95% CI: 2.30–3.35), as well as a significant association
with overweight (HR= 1.45, 95% CI: 1.24–1.68). Furthermore,
excess body weight increased the risk of postmenopausal breast
cancer (overweight HR= 1.13, 95% CI: 1.00–1.27) and the
association with obesity was of borderline significance (HR=
1.20, 95% CI: 1.00–1.44; p= 0.05). In addition, excess body weight
was significantly associated with colorectal (overweight HR= 1.12,
95% CI: 1.01–1.25), colon (overweight HR= 1.21, 95% CI:
Table 1. Population characteristics by body mass index (BMI) category at enrolment
BMI category (kg/m2)
Na Underweight Normal weight Overweight Obesity
Number of women, n (%) 135,708 3022 (2.2) 87,595 (64.6) 34,656 (25.5) 10,435 (7.7)
Obesity-related cancer, n 9328 173 5689 2603 863
Characteristics at enrolmentb
Age (y), mean (SD) 135,708 44.1 (8.4) 46.9 (8.4) 50.8 (8.4) 51.5 (8)
Weight (kg), mean (SD) 135,708 49.3 (3.9) 61.4 (6.1) 74.2 (6.3) 91.0 (11.7)
Height (cm), mean (SD) 135,708 166.6 (5.6) 166.5 (5.6) 165.9 (5.7) 165.3 (5.8)
Education (y) % 128,948
< 10 24.0 21.7 29.8 34.3
10–12 22.1 23.5 24.6 24.4
> 12 53.9 54.9 45.6 41.3
Physical activity level % 123,531
Low 25.7 21.2 30.7 45.7
Moderate 37.5 42.2 42.6 37.0
High 36.8 36.7 26.7 17.4
Smoking status % 135,231
Never smoker 27.2 34.4 37.8 40.0
Former smoker 21.3 31.8 35.7 36.2
Current smoker 51.6 33.8 26.5 23.8
Alcohol intake (g/day), median 128,046 1.6 1.9 1.5 0.9
Age at menarche (y), mean (SD) 133,625 13.7 (1.4) 13.4 (1.4) 13.2 (1.4) 12.9 (1.4)
Age at first full-term pregnancy (y), mean (SD) 123,592 24.7 (4.7) 24.1 (4.4) 23.6 (4.3) 23.4 (4.4)
Parity % 135,708
Nulliparous 13.0 9.5 8.1 11.1
1–2 children 56.8 55.7 50.1 46.3
≥ 3 children 30.2 34.9 41.9 42.6
Oral contraceptive use % 131,415
Never 38.2 40.6 49.8 54.4
Ever 61.8 59.4 50.2 45.6
Menopausal status % 135,708
Premenopausal 64.0 55.3 37.1 31.6
Perimenopausal 4.2 4.8 5.6 6.6
Postmenopausal 25.9 32.9 50.1 54.7
Unknown 5.9 7.0 7.2 7.2
Age at menopause (y), mean (SD) 45,160 46.7 (5.9) 48.3 (4.8) 48.8 (4.7) 48.5 (5.2)
Hormone therapy use % 126,669
Never 85.7 79.6 72.7 73.7
Former 5.6 8.2 12.9 14.4
Current 8.7 12.2 14.4 11.9
The Norwegian Women and Cancer study 1991–2005 (n= 135, 708)
aN is the total amount of responses for the specific variable
bOverall differences between weight change categories were significant for all variables (p < 0.001)
y years, SD standard deviation
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Table 2. Hazard ratio (HR) with 95% confidence interval (CI) for obesity-related cancer risk by body mass index (BMI) category at enrolment
Model 1 age-adjusted Model 2 multivariable
N Cancer cases HR 95% CI N Cancer cases HR 95% CI
Overall obesity-related cancera
Underweight 3022 173 0.95 0.82–1.10 2626 149 0.92 0.78–1.08
Normal weight 87,595 5689 1.00 Reference 77,064 4961 1.00 Reference
Overweight 34,656 2603 1.10 1.05–1.15 29,517 2154 1.09 1.03–1.14
Obesity 10,435 863 1.26 1.17–1.35 8706 699 1.24 1.14–1.34
5 BMI unit increment 135,708 9328 1.11 1.08–1.14 117,913 7 963 1.10 1.07–1.13
Postmenopausal breast cancerb
Underweight 899 27 0.96 0.66–1.41 650 19 0.98 0.62–1.55
Normal weight 32,831 1047 1.00 Reference 24,224 730 1.00 Reference
Overweight 19,270 638 1.04 0.95–1.15 14,079 448 1.13 1.00–1.27
Obesity 6331 206 1.07 0.92–1.24 4540 139 1.20 1.00–1.44
5 BMI unit increment 59,331 1918 1.03 0.97–1.08 43,493 1 336 1.07 1.00–1.15
Colorectal cancerc
Underweight 3022 39 1.11 0.80–1.52 2902 38 1.10 0.80–1.52
Normal weight 87,595 1 146 1.00 Reference 83,411 1083 1.00 Reference
Overweight 34,656 585 1.12 1.02–1.24 32,511 544 1.12 1.01–1.25
Obesity 10,435 157 1.05 0.88–1.24 9744 140 1.01 0.84–1.20
5 BMI unit increment 135,708 1 927 1.05 0.99–1.11 128,568 1 805 1.04 0.98–1.11
Colon cancerd
Underweight 3022 26 1.14 0.77–1.69 3017 26 1.13 0.76–1.67
Normal weight 87,595 746 1.00 Reference 87,355 743 1.00 Reference
Overweight 34,656 414 1.20 1.06–1.36 34,481 411 1.21 1.07–1.37
Obesity 10,435 104 1.05 0.85–1.29 10,378 103 1.06 0.86–1.30
5 BMI unit increment 135,708 1 290 1.06 0.99–1.14 135,231 1 283 1.07 0.99–1.14
Rectal cancere
Underweight 3022 13 1.05 0.60–1.82 2805 11 0.99 0.54–1.81
Normal weight 87,595 400 1.00 Reference 79,948 354 1.00 Reference
Overweight 34,656 171 0.98 0.82–1.18 30,665 153 1.02 0.84–1.24
Obesity 10,435 53 1.05 0.78–1.40 9189 44 1.03 0.75–1.42
5 BMI unit increment 135,708 637 1.03 0.93–1.14 122,607 562 1.04 0.93–1.16
Endometrial cancerf
Underweight 2914 11 0.62 0.34–1.13 2594 10 0.63 0.34–1.18
Normal weight 83,620 539 1.00 Reference 74,239 489 1.00 Reference
Overweight 32,163 321 1.50 1.30–1.72 27,991 277 1.45 1.24–1.68
Obesity 9617 186 3.02 2.55–3.58 8326 156 2.78 2.30–3.35
5 BMI unit increment 128,314 1057 1.53 1.45–1.62 113150 932 1.51 1.42–1.60
Ovarian cancerg
Underweight 2991 11 0.75 0.41–1.36 2851 10 0.71 0.38–1.33
Normal weight 86,442 429 1.00 Reference 81,300 404 1.00 Reference
Overweight 33,816 149 0.91 0.75–1.10 31,608 142 0.92 0.76–1.12
Obesity 10,118 53 1.13 0.85–1.51 9425 49 1.09 0.81–1.48
5 BMI unit increment 133,367 642 1.01 0.91–1.12 125,148 605 1.00 0.90–1.12
Pancreatic cancerc
Underweight 3059 5 0.75 0.31–1.83 2902 4 0.55 0.20–1.48
Normal weight 88,480 213 1.00 Reference 83,411 202 1.00 Reference
Overweight 35,092 104 1.11 0.87–1.41 32,511 97 1.18 0.92–1.51
Obesity 10,574 28 1.05 0.70–1.56 9744 29 1.19 0.79–1.79
5 BMI unit increment 135,708 350 1.02 0.89–1.17 128,568 324 1.11 0.96–1.27
Kidney cancerh
Underweight 3059 2 0.40 0.10–1.60 2295 2 0.50 0.12–2.04
Normal weight 88,480 158 1.00 Reference 68,745 120 1.00 Reference
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1.07–1.37) and kidney cancer (obesity HR= 1.95, 95% CI:
1.26–3.02). An increment of five BMI units was significantly
associated with increased risk of overall obesity-related cancer,
postmenopausal breast cancer, endometrial and kidney cancer.
There was no significant association between excess body weight
and increased risk of rectal, ovarian and pancreatic cancer.
Further, a clear dose–response relationship with increasing BMI
was found for overall obesity-related cancer, endometrial and
kidney cancer (Fig. 2). These dose–response relationships were
statistically significant at different BMI; kidney cancer was
statistically significant only after BMI 30, whereas overall obesity-
related cancer and endometrial cancer were statistically significant
at BMI 24 (Supplementary Information, Table S3–5). We found no
statistically significant interactions between HT use and BMI;
however, menopausal status modified the effect of BMI in relation
to endometrial cancer risk with a statistically significant interaction
between perimenopausal status and obesity. We performed
stratified analysis by menopausal status (Supplementary Informa-
tion, Table S2) but the subgroup analysis result should be
interpreted with caution due to the low number of cases (58) in
the perimenopausal status group.
Weight change and obesity-related cancer risk
Weight gain was significantly associated with increased obesity-
related cancer risk, with associations observed among women
with low weight gain (HR= 1.14, 95% CI: 1.05–1.23), moderate
weight gain (HR= 1.14, 95% CI: 1.05–1.25) and high weight gain
(HR= 1.16, 95% CI: 1.04–1.31), versus stable weight (Table 3). High
weight gain was further significantly associated with nearly a
twofold increased risk in pancreatic cancer (HR= 1.91, 95% CI:
1.11–3.30), also moderate weight gain increased the risk of
pancreatic cancer (HR= 1.60, 95% CI: 1.03–2.47). Furthermore,
weight gain increased the risk of postmenopausal breast cancer
(moderate weight gain HR= 1.20, 95% CI: 1.01–1.43; high weight
gain HR= 1.36, 95% CI: 1.08–1.71), as well as colorectal (moderate
weight gain HR= 1.24, 95% CI: 1.05–1.48), rectal (low weight gain
HR= 1.37, 95% CI: 1.00–1.86; moderate weight gain HR= 1.38,
95% CI: 1.00–1.91; p= 0.05) and endometrial cancer (moderate
weight gain HR= 1.27, 95% CI: 1.01–1.61; high weight gain HR=
1.40, 95% CI: 1.04–1.88). Weight loss was significantly associated
with an increased risk of colorectal cancer (HR= 1.25, CI:
1.01–1.55) and displayed positive associations with all obesity-
related cancers under study, although they did not reach
statistical significance. A 5 kg increase in weight was significantly
associated with increased risk of overall obesity-related cancer,
postmenopausal breast cancer and endometrial cancer. We found
no significant association between weight change and the risk of
colon, ovarian and kidney cancer.
When we allowed for non-linearity, we found a clear
dose–response relationship with increasing weight gain for overall
obesity-related cancer, postmenopausal breast cancer, endome-
trial and pancreatic cancer (Fig. 3). The increase in risk for these
cancers was significant already with low or moderate weight gain
(Supplementary Information, Table S6–9). There was no evidence
of a significant interaction between BMI and weight change
category in relation to overall and specific obesity-related cancer
risk, which was further confirmed by the stratified analysis
(Supplementary Information, Table S10). In addition, we found
no significant interactions between HT use or menopausal status
and weight change category.
DISCUSSION
In this study, we assessed the relationship between BMI, weight
change and obesity-related cancer risk in a large and nationally
representative cohort of women in Norway. We found that
overweight and obesity increased overall obesity-related cancer
risk by 9 and 24%. Furthermore, weight gain < 10 kg over 6 years,
increased obesity-related cancer risk by 14%, whereas gaining
10 kg or more increased the risk by 16%, independent of BMI
status at baseline. These findings highlight the health risks of
excess body weight and increase in body weight among middle-
aged women in Norway. Thus, maintaining stable weight is of
utmost importance for the prevention of overall obesity-related
cancer, especially as the increase in risk started at low levels of
weight gain and most women gained weight. As in other studies,
we found clear evidence of a significant association between
excess body weight and postmenopausal breast, colorectal,
colon, endometrial and kidney cancer,2 but no significant
association with rectal, ovarian or pancreatic cancer. In addition,
we found significant associations between weight gain and
postmenopausal breast, colorectal, rectal, endometrial and
pancreatic cancer but not between weight gain and ovarian
and kidney cancer. These results suggest a similar effect of excess
body weight and weight gain on hormone-related cancers
(postmenopausal breast, endometrial and ovarian cancer), but a
differential effect on kidney, colon, rectal and pancreatic cancer.
Excess body weight and weight gain may affect organs
differently, depending on the mechanism of cancer develop-
ment.19 For instance, pancreatic cancer was not significantly
associated with excess body weight, but there was a significant
positive association with moderate and high weight gain.
Table 2 continued
Model 1 age-adjusted Model 2 multivariable
N Cancer cases HR 95% CI N Cancer cases HR 95% CI
Overweight 35,092 94 1.41 1.08–1.82 26,124 62 1.32 0.96–1.81
Obesity 10,574 38 1.97 1.38–2.83 7502 27 1.95 1.26–3.02
5 BMI unit increment 135,708 292 1.34 1.18–1.51 104,666 211 1.33 1.15–1.54
aModel 2 for overall obesity-related cancer was adjusted for age, education, physical activity and smoking status
bOnly in women who were postmenopausal at enrolment, model 2 for postmenopausal breast cancer was adjusted for age, education, alcohol intake, parity/
age at first full-term pregnancy, oral contraceptive use, hormone therapy use and history of breast cancer in the mother
cModel 2 for colorectal and pancreatic cancer was adjusted for age, education and smoking status
dModel 2 for colon cancer was adjusted for age and smoking status
eModel 2 for rectal cancer was adjusted for age, education and alcohol intake
fModel 2 for endometrial cancer was adjusted for age, education, age at menarche, parity/age at first full-term pregnancy, oral contraceptive use and
menopausal status
gModel 2 for ovarian cancer was adjusted for age, parity/age at first full-term pregnancy and oral contraceptive use
hModel 2 for kidney cancer was adjusted for age, smoking status and diabetes
The Norwegian Women and Cancer study, 1991–2014 (n= 135,708)
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Pancreatic cancer development could be related to increased
insulin levels and higher bioavailability of insulin-like growth
factor,20 in which weight gain, rather than BMI, may play a more
essential role. Our findings on weight gain and pancreatic cancer
is novel. To the best of our knowledge, there has only been one
previous study that included a separate analysis of pancreatic
cancer and weight change in women, and it showed a non-
significant, negative association.21 Another study including both
women and men, demonstrated a non-significant, positive
association.22 These two studies were included in a recent
meta-analysis of weight gain and several cancers, wherein the
authors hypothesised that in the presence of strong risk factors
such as smoking, weight gain is not able to establish itself as an
individual risk factor for pancreatic cancer.4 Our study sample
included 170 pancreatic cancer cases, and we showed a
significant association of moderate and high weight gain with
pancreatic cancer risk, which remained after including smoking
and smoking transition as potential confounders. Thus, our results
suggest a possible role of weight development in the aetiology of
pancreatic cancer, which must be confirmed by future studies,
particularly among women. Kidney cancer is also an obesity-
related cancer less-commonly diagnosed and we found only one
previous study on weight change and kidney cancer in women.23
This aforementioned study showed no association with weight
gain, consistent with our findings. On the contrary, obesity is
reported as a strong predictor of kidney cancer,2 which is in line
with our results of a 95% increased risk of kidney cancer among
women with obesity.
Obesity, moderate and high weight gain were significantly
associated with increased risk of postmenopausal breast cancer,
which is in accordance with previous studies.4,24 The risk of
postmenopausal breast cancer was higher in women experiencing
moderate and high weight gain than among women with obesity,
suggesting that weight gain may have an influence on
postmenopausal breast cancer development beyond that of body
composition. In our study, overweight, but not obesity, was
associated with an increased risk of colorectal/colon cancer. This
result may have been influenced by reverse causality, namely that
weight loss was an early, pre-clinical symptom of colorectal
cancer. There is inconsistency across studies on the association
between weight change and colorectal cancer in women, with
different results for colon and rectal cancers, but an overall
indication of no association.4,25 We found a positive significant
association between weight loss and moderate weight gain and
colorectal cancer, but there was no significant association
between high weight gain and colorectal cancer. For rectal
cancer, we found a significant association for low and moderate
weight gain but not high weight gain. Although we excluded all
women with follow-up < 2 years, we can still not entirely rule out
reverse causality, as we cannot differentiate between intentional
and unintentional weight loss. In fact, studies of cancer incidence
in women with obesity who have undergone bariatric surgery,
show a decrease in overall and female-specific (breast and
gynaecological) cancer risk compared with controls, suggesting
that intentional weight loss may decrease cancer risk.26 However,
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Fig. 2 Non-linear effects of BMI at enrolment and risk of specific and overall obesity-related cancers, with 95% CI. Restricted cubic splines were
fitted with knots at BMI 19, 22, 25 and 31. P values are for non-linearity
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Table 3. Hazard ratio (HR) with 95% confidence interval (CI) for obesity-related cancer risk by weight change category between the enrolment (Q1)
and follow-up questionnaire (Q2)
Model 1 age-adjusted Model 2 Multivariable
N Cancer cases HR 95% CI N Cancer cases HR 95% CI
Overall obesity-related cancera
Weight loss (<−2kg) 7876 478 1.15 1.04–1.28 6886 406 1.09 0.97–1.22
Stable weight (−2– < 2 kg) 23,711 1315 1.00 Reference 20,950 1 142 1.00 Reference
Low weight gain (2– < 5 kg) 22,362 1356 1.10 1.02–1.19 19,844 1 209 1.14 1.05–1.23
Moderate weight gain (5– < 10 kg) 19,495 1218 1.14 1.06–1.24 17,202 1 069 1.14 1.05–1.25
High weight gain (≥ 10 kg) 7486 464 1.19 1.06–1.32 6558 406 1.16 1.04–1.31
5 kg increment 80,930 4831 1.02 1.00–1.05 71,440 4 232 1.03 1.00–1.07
Postmenopausal breast cancerb
Weight loss (<−2kg) 5456 128 1.00 0.82–1.22 4040 97 1.16 0.92–1.47
Stable weight (−2– < 2 kg) 14,997 388 1.00 Reference 11,605 277 1.00 Reference
Low weight gain (2– < 5 kg) 12,462 383 1.11 0.97–1.28 9858 293 1.16 0.98–1.36
Moderate weight gain (5– < 10 kg) 10,103 312 1.08 0.93–1.25 8025 254 1.20 1.01–1.43
High weight gain (≥ 10 kg) 3690 121 1.15 0.93–1.41 2924 102 1.36 1.08–1.71
5 kg increment 46,708 1 332 1.04 0.98–1.09 36,452 1023 1.08 1.02–1.14
Colorectal cancerc
Weight loss (<−2kg) 7876 120 1.28 1.03–1.58 7874 120 1.25 1.01–1.55
Stable weight (−2– < 2 kg) 23,711 286 1.00 Reference 23,705 286 1.00 Reference
Low weight gain (2– < 5 kg) 22,362 273 1.11 0.94–1.31 22,361 273 1.11 0.94–1.32
Moderate weight gain (5– < 10 kg) 19,495 253 1.24 1.05–1.48 19,492 252 1.24 1.05–1.48
High weight gain (≥ 10 kg) 7486 75 1.04 0.8–1.34 7486 75 1.02 0.79–1.33
5 kg increment 80,930 1007 0.99 0.94–1.06 80,918 1006 1.00 0.94–1.06
Colon cancerd
Weight loss (<−2kg) 7876 91 1.30 1.01–1.66 7872 91 1.26 0.98–1.61
Stable weight (−2– < 2 kg) 23,711 212 1.00 Reference 23,695 210 1.00 Reference
Low weight gain (2– < 5 kg) 22,362 181 1.01 0.83–1.24 22,355 181 1.03 0.84–1.26
Moderate weight gain (5– < 10 kg) 19,495 174 1.19 0.97–1.47 19,487 173 1.19 0.97–1.46
High weight gain (≥ 10 kg) 7486 52 1.01 0.74–1.38 7483 52 0.98 0.72–1.34
5 kg increment 80,930 710 0.98 0.91–1.05 80,892 707 0.98 0.91–1.05
Rectal cancere
Weight loss ( <−2kg) 7876 29 1.22 0.80–1.88 7876 29 1.22 0.80–1.88
Stable weight (−2 to < 2 kg) 23,711 74 1.00 Reference 23,711 74 1.00 Reference
Low weight gain (2 to < 5 kg) 22,362 92 1.37 1.00–1.86 22,362 92 1.37 1.00–1.86
Moderate weight gain (5 to < 10 kg) 19,495 79 1.38 1.00–1.91 19,495 79 1.38 1.00–1.91
High weight gain ( ≥ 10 kg) 7486 23 1.11 0.69–1.78 7486 23 1.11 0.69–1.78
5 kg increment 80,930 297 1.03 0.92–1.15 80,930 297 1.03 0.92–1.15
Endometrial cancerf
Weight loss (<−2kg) 7281 59 1.24 0.92–1.68 6813 55 1.03 0.75–1.41
Stable weight (−2– < 2 kg) 22,238 153 1.00 Reference 20,899 139 1.00 Reference
Low weight gain (2– < 5 kg) 20,998 136 0.94 0.75–1.19 19,798 127 0.99 0.78–1.26
Moderate weight gain (5– < 10 kg) 18,389 154 1.23 0.98–1.54 17,413 150 1.27 1.01–1.61
High weight gain (≥ 10 kg) 6989 69 1.51 1.13–2.01 6674 68 1.40 1.04–1.88
5 kg increment 75,895 571 1.10 1.02–1.19 71,597 539 1.12 1.04–1.20
Ovarian cancerg
Weight loss (<−2kg) 7614 37 1.62 1.09–2.41 6650 30 1.52 0.99–2.34
Stable weight (−2– < 2 kg) 23,041 74 1.00 Reference 20,409 66 1.00 Reference
Low weight gain (2– < 5 kg) 21,890 90 1.25 0.92–1.71 19,497 84 1.29 0.93–1.79
Moderate weight gain (5– < 10 kg) 19,133 84 1.32 0.96–1.81 16,955 75 1.30 0.93–1.82
High weight gain (≥ 10 kg) 7345 25 1.05 0.66–1.66 6511 23 1.08 0.67–1.74
5 kg increment 79,023 310 0.96 0.86–1.06 70,022 278 0.98 0.87–1.10
Pancreatic cancerh
Weight loss (<−2kg) 7876 25 1.84 1.12–3.02 7176 21 1.58 0.93–2.69
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differentiate intentional and unintentional weight loss are
warranted to improve our understanding of the effect of weight
loss on cancer risk.
Endometrial cancer was strongly associated with obesity with
a threefold elevated risk compared with women in normal
weight. Moderate and high weight gain also increased the risk
of endometrial cancer but the association for weight gain was
not as strong as that for excess body weight. The evidence for
a positive association between obesity, weight change and
endometrial cancer risk is consistent with other studies.24,27,28
However, many studies on weight gain and endometrial cancer
risk reported an increased risk only for substantially higher weight
gain categories than those included in our study,29–31 whereas we
report an increased risk starting at moderate weight gain.
The main strength of our study is its large, nationally
representative, population-based sample of women in Norway
with long follow-up time. The comprehensive questionnaires
enabled us to control for important confounders such as
anthropometric, sociodemographic, lifestyle, reproductive and
menopausal factors, and the linkage with the Norwegian Cancer
Registry provided us with virtually complete cancer case
ascertainment. Thanks to the sample size and the extensiveness
of the Norwegian Cancer Registry, we had the possibility to assess
overall obesity-related cancer, and both common and less-
common site-specific obesity-related cancers. There have been
very few published articles on weight change and incidence of
pancreatic and kidney cancer in women, and here we have added
evidence to the current literature. Nevertheless, this study has
several limitations. Height and weight were self-reported, and
there is a well-established tendency to overestimate height as well
as underestimate weight that increases with age and BMI.32 In our
study, we assume that the potential misclassification due to this
information bias was non-differential between cases and non-
cases. Therefore, our risk estimates may have been under-
estimated. Furthermore, a validation study of BMI has been
conducted in the NOWAC study and showed substantial agree-
ment between self-reports and objective measurements.33
In addition, the covariate physical activity was also self-reported
and displayed a moderate significant correlation with heart
rate and movement in a previous validation study.34 Total
energy intake was omitted from the analyses because the food-
frequency questionnaire was not provided to all participants in
this study, leading to a large amount of missing data (61%), and
because of known biases with respect to obesity.35 Finally, as
mentioned above, the lack of information on intentionality of
weight loss to avoid reverse causality hampered the weight loss
analysis.
The mean BMI in our study sample was 24.1. Thus, our study
sample is slimmer than in many other high-income countries.36 The
generalisability of our study is restricted to women in Norway but it
is unlikely that the association between excess body weight/weight
gain and obesity-related cancer substantially differs across regions.
However, the impact of our findings, i.e., the number of cancer cases
attributable to excess body weight and weight gain (given a causal
relationship) may potentially be larger in regions with higher
prevalence of excess body weight or higher weight gain.
In summary, maintaining stable weight in middle adulthood,
regardless BMI status, and avoiding excess body weight are
important for the prevention of several obesity-related cancers.
We found strong associations between obesity and endometrial
cancer risk, and high weight gain and pancreatic cancer risk. Our
findings on weight gain and pancreatic cancer risk are particularly
interesting given the increasing incidence of pancreatic cancer in
women in Norway, and the very poor prognosis of the disease.8 If
our findings are confirmed, avoidance of weight gain could be
considered a potential preventive measure for pancreatic cancer.
Table 3 continued
Model 1 age-adjusted Model 2 Multivariable
N Cancer cases HR 95% CI N Cancer cases HR 95% CI
Stable weight (−2– < 2 kg) 23,711 42 1.00 Reference 21,697 39 1.00 Reference
Low weight gain (2– < 5 kg) 22,362 50 1.37 0.91–2.07 20,641 43 1.28 0.83–1.98
Moderate weight gain (5– < 10 kg) 19,495 48 1.59 1.04–2.43 18,124 46 1.60 1.03–2.47
High weight gain (≥ 10 kg) 7486 21 1.95 1.14–3.32 6971 21 1.91 1.11–3.30
5 kg increment 80,930 186 1.09 0.95–1.26 74,609 170 1.12 0.97–1.29
Kidney canceri
Weight loss (<−2kg) 7876 17 1.29 0.73–2.28 5750 10 1.08 0.52–2.27
Stable weight (−2– < 2 kg) 23,711 41 1.00 Reference 18,350 26 1.00 Reference
Low weight gain (2– < 5 kg) 22,362 40 1.07 0.69–1.66 17,697 27 1.14 0.66–1.96
Moderate weight gain (5– < 10 kg) 19,495 35 1.10 0.70–1.74 15,223 23 1.14 0.64–2.01
High weight gain (≥ 10 kg) 7486 15 1.31 0.72–2.38 5634 8 1.10 0.49–2.45
5 kg increment 80,930 148 1.05 0.90–1.23 62,654 94 1.09 0.90–1.31
The Norwegian Women and Cancer study, 1991–2014 (n= 80,930)
aModel 2 for obesity-related cancer was adjusted for age, BMI (Q1), physical activity (Q1), smoking status and smoking transition
bOnly in women who were postmenopausal at Q2, model 2 for postmenopausal breast cancer was adjusted for age, education, parity/age at first full-term
pregnancy, hormone therapy use and history of breast cancer in the mother
cModel 2 for colorectal cancer was adjusted for age and smoking status
dModel 2 for colon cancer was adjusted for age, BMI (Q1) and smoking status
eModel 2 for rectal cancer did not significantly differ from model 1 and was only adjusted for age
fModel 2 for endometrial cancer was adjusted for age, BMI (Q1), age at menarche, parity/age at first full-term pregnancy, oral contraceptive use and
menopausal status
gModel 2 for ovarian cancer was adjusted for age, physical activity (Q1) and parity/age at first full-term pregnancy
hModel 2 for pancreatic cancer was adjusted for age, education and smoking status
iModel 2 for kidney cancer was adjusted for age, alcohol intake and diabetes
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